ClinicalTrials.gg
RecruitingNCT06903858PICC-3Updated May 22, 2026

Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer

A Phase 2 interventional study of Toripalimab plus celecoxib and Non-operative management in Colorectal Cancer, Microsatellite Instability High and Mismatch Repair Deficiency, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Primary conditionTurcot syndromeRegistry: Colorectal NeoplasmsReclassifiedWhy we changed it
Registry
Colorectal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Turcot syndrome
Why
  1. The study's listed conditions name Turcot syndrome, a narrower term within Colorectal Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Turcot syndrome with a site in China — 7 open to participants now, 10 under way, none of them phase 3. Turcot syndrome · China.

Planned enrollment
4th of 11
105 · median 28
Started
2025
the only one that year
Phase 2
7 of 12
5 open now
Registered
11th of 12
by date
Lead sponsor
4 of 12
Sun Yat-sen University

Among the 12 studies in Turcot syndrome with a site in China, this one is the 4th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 7 in phase 2, and was the 11th registered.

Turcot syndrome

60 studies on the registry are indexed under Turcot syndrome; 29 are open to participants now.

Browse Turcot syndrome studies →

Open to participants now

7 of the 12 studies in Turcot syndrome with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Turcot syndrome studies recruiting now, 16 (84%) set no upper age limit and 2 (11%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Turcot syndrome with a site in China, or all of them as a file.
02

Study summary

The PICC-3 study is a multicentre, single-arm, phase II trial evaluating toripalimab plus celecoxib in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer. The trial uses a response-adapted treatment strategy, whereby patients with clinical complete response (cCR) after therapy may enter a non-operative management pathway, while patients without cCR proceed to surgery. Response assessment is based on imaging, endoscopy, biopsy evaluation, and ctDNA analysis.

Read the detailed description

Patients with dMMR/MSI-H locally advanced colorectal cancer have shown high sensitivity to neoadjuvant immune checkpoint inhibitor. Several phase II studies have demonstrated high rates of clinical complete response (cCR) and pathological complete response (pCR), supporting the feasibility and safety of immunotherapy in localized dMMR/MSI-H colorectal cancer.

Radical surgery for locally advanced colorectal cancer is associated with substantial perioperative morbidity and long-term functional consequences. In particular, total mesorectal excision for rectal cancer may result in bowel, urinary, and sexual dysfunction, and some patients may require temporary or permanent stoma formation. Therefore, organ preservation and non-operative management have become important treatment goals for selected patients with colorectal cancer who achieve complete clinical response after neoadjuvant therapy.

Previous studies have demonstrated the feasibility and safety of non-operative management after immune checkpoint inhibitor in patients with dMMR/MSI-H rectal cancer, while emerging evidence suggests that this strategy may also be feasible in selected patients with colon cancer following immunotherapy.

03

Conditions studied

  • Colorectal Cancer
  • Microsatellite Instability High
  • Mismatch Repair Deficiency

Browse trials for

Keywords

  • PD-1 blockade
  • Toripalimab
  • COX-2 inhibitor
  • Celecoxib
  • Non-operative Management
04

In context

Turcot syndrome Reclassified

60 studies on the registry are indexed under Turcot syndrome; 29 are open to participants now.

This study's planned enrollment of 105 is above the median of 38 across 45 interventional studies indexed under Turcot syndrome.

Browse Turcot syndrome studies →

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,695 studies on the registry; 622 are open to participants now.

Compared within Turcot syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Colorectal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and willingness/compliance with study procedures.
  2. Age ≥18 years.
  3. confirmed colorectal adenocarcinoma.
  4. performance status 0-1.
  5. Locally advanced primary tumor (T3/T4 and/or N+) confirmed by CT/MRI (pelvic MRI for rectal cancer).
  6. dMMR (IHC) or MSI-H (PCR) status.
  7. No prior anti-cancer therapy for colonrectal cancer (surgery/chemotherapy/targeted therapy/radiation).
  8. Adequate organ function
  9. For women of : negative pregnancy test and use during and for 3 months post-treatment. Male participants with fertile partners must use contraception.
  10. Willingness to adhere to study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Presence of distant (M1) confirmed by CT/MRI or PET-CT (at least covering the chest, abdomen, and pelvis).
  2. Complete intestinal obstruction, active bleeding, or perforation requiring emergency surgery.
  3. Inability to achieve complete resection of the primary colorectal tumor.
  4. History or concurrent active (except malignancies cured ≥5 years ago or adequately treated carcinoma in situ).
  5. Prior treatment with /PD-L1 antibodies, anti-CTLA-4 antibodies, or other drugs/antibodies targeting T-cell co-stimulation or checkpoint pathways.
  6. Major surgery (e.g., laparotomy, thoracotomy, organ resection via laparoscopy) or severe trauma within 4 weeks before enrollment (surgical incision must be fully healed).
  7. Thromboembolic events (e.g., cerebrovascular accident, , pulmonary embolism, deep vein thrombosis) within 12 months before enrollment.
  8. Active coronary artery disease, severe/unstable angina, or newly diagnosed angina/myocardial infarction within 12 months before enrollment.
  9. (NYHA) Class II or higher congestive heart failure (see Appendix 3).
  10. infection, AIDS, or untreated active hepatitis ( ≥500 IU/mL; above detection limit).
  11. Active inflammatory bowel disease or other colorectal disorders causing chronic diarrhea.
  12. Active, known, or suspected disease (exceptions: stable conditions like type 1 diabetes, hypothyroidism on hormone replacement, or skin disorders without systemic treatment, e.g., vitiligo, psoriasis, alopecia).
  13. Interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases (e.g., diabetes, hypertension, pulmonary fibrosis, acute pneumonia).
  14. Residual toxicity ≥Grade 2 (per v5.0) from prior therapies (except anemia, alopecia, skin pigmentation).
  15. Known or suspected to any study-related drugs.
  16. Pregnancy or lactation.
  17. Women of (last menstruation \<2 years ago) or fertile men unwilling to use effective non-hormonal .
  18. Any unstable medical condition compromising safety or protocol compliance.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Toripalimab plus celecoxib

    Toripalimab is administered intravenously at 3 mg/kg over 30 minutes once every 2 weeks for a total of 12 doses. Celecoxib is administered orally at 200 mg twice daily for 6 months. Patients achieving clinical complete response (cCR) are recommended for non-operative management, whereas patients without cCR are recommended to undergo curative-intent surgery.

    Drug: Toripalimab plus celecoxib · Procedure: Non-operative management · Procedure: Curative-intent surgery

Interventions

  • DrugToripalimab plus celecoxib

    Drug pages: ToripalimabStudies of ToripalimabToripalimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CelecoxibStudies of CelecoxibCelecoxib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Toripalimab is administered intravenously at 3 mg/kg over 30 minutes once every 2 weeks for a total of 12 doses. Celecoxib is administered orally at 200 mg twice daily for 6 months.

  • ProcedureNon-operative management

    Patients achieving clinical complete response (cCR) according to comprehensive response assessment, including imaging, endoscopy, digital rectal examination (if applicable), and ctDNA evaluation, may undergo non-operative management.

  • ProcedureCurative-intent surgery

    Patients who do not achieve cCR will undergo curative-intent surgery.

07

What researchers measure

Primary outcomes

  1. Event-free survival (EFS)

    the time from the first dose of study treatment to the occurrence of one of the following events: locally progressive disease of the primary tumour precluding curative-intent surgery, R2 resection, local recurrence after R0 or R1 resection, unsalvageable local regrowth during non-operative management, distant metastasis, a second primary colorectal cancer, or death from any cause, whichever occurs first.

    Time frame: 3 years

Secondary outcomes

  1. Pathological complete response (pCR) rate

    the percentage of subjects with no residual viable tumor in the resected primary tumor specimen and all sampled regional lymph nodes after radical surgery (ypT0N0).

    Time frame: 3 years

  2. Clinical complete response (cCR) rate

    the percentage of subjects achieving no evidence of residual tumour on comprehensive response assessment, including imaging, endoscopy with negative biopsy findings, digital rectal examination (if applicable), and ctDNA evaluation.

    Time frame: 3 years

  3. Complete response (CR) rate

    the percentage of subjects achieving pathological complete response (pCR) after surgery or clinical complete response (cCR) with non-operative management.

    Time frame: 3 years

  4. Overall survival (OS)

    the time from the first dose of study treatment to death from any cause.

    Time frame: 5 years

  5. Incidence of treatment-related adverse events

    incidence and severity of treatment-related adverse events, graded according to CTCAE version 5.0.

    Time frame: 3 years

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Apr 2028, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
Apr 1, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Apr 1, 2028
CompletionEst.
Apr 1, 2031
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06903858
Responsible party
Yanhong Deng (Professor, Sixth Affiliated Hospital, Sun Yat-sen University) — Principal investigator
First posted
Apr 1, 2025
Start date
Jun 1, 2025
Primary completion
Apr 1, 2028 (estimated)
Completion
Apr 1, 2031 (estimated)
Last update
May 22, 2026

Study contacts

Yanhong Deng, MD.
Contact
dengyanh@mail.sysu.edu.cn
020-38379762

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Toripalimab · Celecoxib

Start the discussion